Rhythm Pharmaceuticals Inc
NASDAQ:RYTM
Rhythm Pharmaceuticals Inc
NASDAQ:RYTM
Price:
35.68 USD
-2.73%
Market Closed
Updated:
Jun 1, 2024
Rhythm Pharmaceuticals Inc
Cash & Cash Equivalents
|
Rhythm Pharmaceuticals Inc
Cash & Cash Equivalents Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Rhythm Pharmaceuticals Inc
NASDAQ:RYTM
|
Cash & Cash Equivalents
$53.4m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash & Cash Equivalents
$18.1B
|
CAGR 3-Years
23%
|
CAGR 5-Years
30%
|
CAGR 10-Years
8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash & Cash Equivalents
$4.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-3%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash & Cash Equivalents
$9.7B
|
CAGR 3-Years
17%
|
CAGR 5-Years
6%
|
CAGR 10-Years
10%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash & Cash Equivalents
$9.2B
|
CAGR 3-Years
13%
|
CAGR 5-Years
26%
|
CAGR 10-Years
36%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash & Cash Equivalents
$2.6B
|
CAGR 3-Years
22%
|
CAGR 5-Years
9%
|
CAGR 10-Years
19%
|
See Also
What is Rhythm Pharmaceuticals Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
53.4m
USD
53.4m
USD
Based on the financial report for Mar 31, 2024, Rhythm Pharmaceuticals Inc's Cash & Cash Equivalents amounts to 53.4m USD.
What is Rhythm Pharmaceuticals Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
5%
5%
Over the last year, the Cash & Cash Equivalents growth was -51%. The average annual Cash & Cash Equivalents growth rates for Rhythm Pharmaceuticals Inc have been -15% over the past three years , 5% over the past five years .
You don't have any saved screeners yet
